Drug Profile
DFP 14927
Alternative Names: DFP 14927Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Delta-Fly Pharma
- Class Antineoplastics
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 07 Feb 2024 Delta-Fly Pharma plans an expanded phase I trial for Colorectal cancer (Second-line therapy or greater) (IV)
- 07 Jan 2024 Delta-Fly Pharma has granted patent for DFP 14927 in combination with Venetoclax (VTX) in Japan, US, and Taiwan
- 07 Jan 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) before January 2024